Dan is a General Partner on the Frazier Life Sciences team and has been involved with investing in and building many of Frazier’s biopharmaceutical portfolio companies over the past 9 years, focusing on investments in both development-stage and commercial-stage pharmaceutical companies. He has led Frazier’s investments in, and serves on the boards of, Arcutis (NASDAQ: ARQT, co-founder) and Cirius Therapeutics. He previously served on the board of Semnur Pharmaceuticals (acquired by Scilex).
Dan has also been involved in Frazier’s investments in Acerta Pharma BV (acquired by AstraZeneca), Tobira Therapeutics (acquired by Allergan), Ignyta (acquired by Roche), ARMO (acquired by Lilly), Iovance (NASDAQ: IOVA), and PreCision Dermatology (acquired by Valeant).
Prior to joining Frazier, Dan was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised leading global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. He received his PhD in Biomedical Engineering from the University of Michigan and holds a BS in Electrical Engineering from Stanford University, where he is a member of Tau Beta Pi.
In 2018, Dan was named a “40-and-under Silicon Valley biotech investing star” by Business Insider.